ES2059588T3 - Factor xiii para la prevencion de una hemorragia intraventricular. - Google Patents

Factor xiii para la prevencion de una hemorragia intraventricular.

Info

Publication number
ES2059588T3
ES2059588T3 ES89102471T ES89102471T ES2059588T3 ES 2059588 T3 ES2059588 T3 ES 2059588T3 ES 89102471 T ES89102471 T ES 89102471T ES 89102471 T ES89102471 T ES 89102471T ES 2059588 T3 ES2059588 T3 ES 2059588T3
Authority
ES
Spain
Prior art keywords
prevention
factor xiii
intraventricular hemorrhage
intraventricular
hemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89102471T
Other languages
English (en)
Spanish (es)
Inventor
Akira Shirahata
Minoru Uchida
Satoshi Tanaka
Kenichiro Tsumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of ES2059588T3 publication Critical patent/ES2059588T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES89102471T 1988-02-24 1989-02-14 Factor xiii para la prevencion de una hemorragia intraventricular. Expired - Lifetime ES2059588T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤

Publications (1)

Publication Number Publication Date
ES2059588T3 true ES2059588T3 (es) 1994-11-16

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89102471T Expired - Lifetime ES2059588T3 (es) 1988-02-24 1989-02-14 Factor xiii para la prevencion de una hemorragia intraventricular.

Country Status (12)

Country Link
US (1) US5114916A (https=)
EP (1) EP0330049B1 (https=)
JP (1) JPH01216939A (https=)
KR (1) KR0137476B1 (https=)
AT (1) ATE94070T1 (https=)
AU (1) AU613154B2 (https=)
CA (1) CA1332352C (https=)
DE (1) DE68908913T2 (https=)
DK (1) DK174978B1 (https=)
ES (1) ES2059588T3 (https=)
IE (1) IE63656B1 (https=)
PT (1) PT89802B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
AU3423493A (en) * 1991-12-31 1993-07-28 Zymogenetics Inc. Methods and compositions for reducing blood loss
US5525335A (en) * 1992-04-21 1996-06-11 Ajinomoto Co., Inc. Wound healing agent
ATE184199T1 (de) * 1992-11-12 1999-09-15 Zymogenetics Inc Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
US20080176789A1 (en) * 2004-08-27 2008-07-24 Novc Nordisk Healthcare A/G Purification of Factor Xlll Polypeptides From Biological Materials
ES2378777T3 (es) * 2004-11-23 2012-04-17 Zymogenetics, Inc. Purificación del factor XIII humano recombinante
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
CN101622270B (zh) * 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DK175919B1 (da) * 1986-09-19 2005-06-27 Univ Washington Ekspression af biologisk aktiv faktor XIII

Also Published As

Publication number Publication date
CA1332352C (en) 1994-10-11
EP0330049A3 (en) 1991-01-30
IE63656B1 (en) 1995-05-31
KR890012659A (ko) 1989-09-18
EP0330049A2 (en) 1989-08-30
PT89802A (pt) 1989-10-04
JPH0378850B2 (https=) 1991-12-17
PT89802B (pt) 1994-04-29
DK174978B1 (da) 2004-04-05
US5114916A (en) 1992-05-19
DK83889A (da) 1989-08-25
DK83889D0 (da) 1989-02-23
KR0137476B1 (ko) 1998-06-01
DE68908913D1 (de) 1993-10-14
JPH01216939A (ja) 1989-08-30
AU3024389A (en) 1989-08-24
IE890580L (en) 1989-08-24
EP0330049B1 (en) 1993-09-08
AU613154B2 (en) 1991-07-25
DE68908913T2 (de) 1994-01-27
ATE94070T1 (de) 1993-09-15

Similar Documents

Publication Publication Date Title
ES2059588T3 (es) Factor xiii para la prevencion de una hemorragia intraventricular.
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
DE69010840D1 (de) Sterile chirurgische Nadel-Nähfaden-Zusammensetzung.
DE3872372D1 (de) Zusammensetzung zur erhoehung der intrazell-atp-spiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
FI870034A7 (fi) Kertakäyttöinen injektioruisku.
DE58900505D1 (de) Medizinischer katheter mit schneidvorrichtung.
NO2002009I2 (no) Tiotropium
ES2001936A6 (es) Procedimiento para la preparacion de indoles sustituidos con heterociclos.
DK0976722T3 (da) Benzamidin-derivater
DK0563093T3 (da) Præparat anvendt som terapeutisk middel mod kroniske virale hepatitissygdomme
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
EP1004304A4 (en) COMPOSITION WITH ACORBIC ACID
ES2085898T3 (es) Tratamiento de la enfermedad hepatobiliar con compuestos 15-cetoprostaglandina.
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
BR9809478A (pt) Uso de um oligossacarìdeo sintético, processos para prevenção de coagulação sanguìnea em um mamìfero e para prevenção de coagulação sanguìnea e um circuito sanguìneo extracorpóreo, e, composição farmacêutica adaptada para prevenir coagulação sanguìnea em um circuito sanguìneo extracorpóreo
DK0430551T3 (da) Behandling af hjertedysfunktion med 15-keto-prostaglandinforbindelser
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
NO872875L (no) Modifisert vevsplasminaktivator, samt fremgangsmŸte for fremstilling av en slik.
SE8802040D0 (sv) New use
ES2058891T3 (es) Preparacion liquida para perfusion intraocular.
IT211928Z2 (it) Cappellotto di cop}rtura degli aghi, particolarmente per siringhe monouso.
EP0412920A3 (fr) Composition pour le diagnostic et/ou le traitement, notamment du cancer
DE68907894D1 (de) Infusionskanuele.
EP0236636A3 (en) Use of clonidine derivatives for the preparation of ocular hemostatic agents
DE3773322D1 (de) Pharmazeutische zubereitungen mit heilender aktivitaet.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330049

Country of ref document: ES